Gilead Sciences Kicks Off Phase 1 Trial of Inhaled Remdesivir for COVID-19

Gilead Sciences has begun a phase 1 trial in the U.S. of an inhaled formulation of its COVID-19 antiviral remdesivir in healthy volunteers.

The initial trial will evaluate the drug in 60 participants aged 18-45. The next stage will study the formulation in COVID-19 patients who have not been hospitalized.

The inhaled formulation of the antiviral drug would be a better delivery option for non-hospitalized COVID-19 patients, the company said.